A Phase I Trial of Pazopanib Suspension Plus Cetuximab in Patients With Incurable Head and Neck Squamous Cell Carcinoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Pazopanib (Primary) ; Cetuximab
- Indications Head and neck cancer
- Focus Adverse reactions
- 26 Jun 2017 Planned End Date changed from 31 Jul 2017 to 31 Dec 2017.
- 26 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 19 Oct 2016 Planned End Date changed from 1 Oct 2016 to 1 Jul 2017.